GlycoMimetics Inc. (Nasdaq: GLYC) reported upbeat updated data from the Phase 1/2 trial for GMI-1271 to treat relapsed/refractory acute myeloid leukemia. The stock price soared $2.13 to close at $16.45.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.